CN111919934A - Safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular and preparation method thereof - Google Patents
Safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular and preparation method thereof Download PDFInfo
- Publication number
- CN111919934A CN111919934A CN202010979113.6A CN202010979113A CN111919934A CN 111919934 A CN111919934 A CN 111919934A CN 202010979113 A CN202010979113 A CN 202010979113A CN 111919934 A CN111919934 A CN 111919934A
- Authority
- CN
- China
- Prior art keywords
- tea
- parts
- safflower
- high blood
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000269722 Thea sinensis Species 0.000 title claims abstract description 161
- 210000004369 blood Anatomy 0.000 title claims abstract description 66
- 239000008280 blood Substances 0.000 title claims abstract description 66
- 244000020518 Carthamus tinctorius Species 0.000 title claims abstract description 58
- 235000003255 Carthamus tinctorius Nutrition 0.000 title claims abstract description 58
- 230000001603 reducing effect Effects 0.000 title claims abstract description 58
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 47
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 title claims description 18
- 235000004347 Perilla Nutrition 0.000 claims abstract description 33
- 244000124853 Perilla frutescens Species 0.000 claims abstract description 32
- 210000002216 heart Anatomy 0.000 claims abstract description 31
- 210000000748 cardiovascular system Anatomy 0.000 claims abstract description 29
- 240000000249 Morus alba Species 0.000 claims abstract description 26
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 26
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 22
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 22
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 22
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 22
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 22
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 22
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 22
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 22
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 22
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 22
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 22
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 22
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 22
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 20
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 20
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 19
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 18
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 18
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 18
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 18
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims abstract description 17
- 244000185386 Thladiantha grosvenorii Species 0.000 claims abstract description 16
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 claims abstract description 16
- 241000219784 Sophora Species 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 15
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 4
- 235000013616 tea Nutrition 0.000 claims description 141
- 239000000706 filtrate Substances 0.000 claims description 52
- 238000002386 leaching Methods 0.000 claims description 50
- 239000000243 solution Substances 0.000 claims description 46
- 238000001914 filtration Methods 0.000 claims description 45
- 238000000605 extraction Methods 0.000 claims description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 29
- 230000002829 reductive effect Effects 0.000 claims description 23
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 21
- 239000006228 supernatant Substances 0.000 claims description 20
- 229910052720 vanadium Inorganic materials 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 19
- 238000004806 packaging method and process Methods 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 238000010438 heat treatment Methods 0.000 claims description 15
- 238000005303 weighing Methods 0.000 claims description 15
- 235000006468 Thea sinensis Nutrition 0.000 claims description 14
- 235000013399 edible fruits Nutrition 0.000 claims description 12
- 201000001421 hyperglycemia Diseases 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 11
- 238000004140 cleaning Methods 0.000 claims description 10
- 239000012535 impurity Substances 0.000 claims description 10
- 238000012216 screening Methods 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 238000009423 ventilation Methods 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 238000005507 spraying Methods 0.000 claims description 9
- 235000020279 black tea Nutrition 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 235000009569 green tea Nutrition 0.000 claims description 6
- 235000020333 oolong tea Nutrition 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 235000020334 white tea Nutrition 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 239000004033 plastic Substances 0.000 claims description 5
- 239000011148 porous material Substances 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 235000020338 yellow tea Nutrition 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 51
- 229940079593 drug Drugs 0.000 abstract description 5
- 235000011194 food seasoning agent Nutrition 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 5
- 230000003203 everyday effect Effects 0.000 abstract description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 26
- 230000036772 blood pressure Effects 0.000 description 20
- 241001092040 Crataegus Species 0.000 description 18
- 210000004185 liver Anatomy 0.000 description 18
- 235000019197 fats Nutrition 0.000 description 15
- 238000011160 research Methods 0.000 description 15
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 12
- 150000003254 radicals Chemical class 0.000 description 12
- 235000012000 cholesterol Nutrition 0.000 description 11
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 11
- 230000001105 regulatory effect Effects 0.000 description 11
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 10
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 201000001320 Atherosclerosis Diseases 0.000 description 9
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 9
- 102000019197 Superoxide Dismutase Human genes 0.000 description 9
- 108010012715 Superoxide dismutase Proteins 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 9
- 230000003647 oxidation Effects 0.000 description 9
- 238000007254 oxidation reaction Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 8
- 229940118019 malondialdehyde Drugs 0.000 description 8
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 8
- 235000005493 rutin Nutrition 0.000 description 8
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 8
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 8
- 229960004555 rutoside Drugs 0.000 description 8
- 231100000240 steatosis hepatitis Toxicity 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 208000004930 Fatty Liver Diseases 0.000 description 7
- 206010019708 Hepatic steatosis Diseases 0.000 description 7
- 230000004438 eyesight Effects 0.000 description 7
- 208000010706 fatty liver disease Diseases 0.000 description 7
- 210000004153 islets of langerhan Anatomy 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 229910052742 iron Inorganic materials 0.000 description 6
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 6
- 150000008442 polyphenolic compounds Chemical class 0.000 description 6
- 235000013824 polyphenols Nutrition 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 5
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229930003935 flavonoid Natural products 0.000 description 5
- 150000002215 flavonoids Chemical class 0.000 description 5
- 235000017173 flavonoids Nutrition 0.000 description 5
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 235000005875 quercetin Nutrition 0.000 description 5
- 229960001285 quercetin Drugs 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 229930013930 alkaloid Natural products 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000003859 lipid peroxidation Effects 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 150000002212 flavone derivatives Chemical class 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 229910001385 heavy metal Inorganic materials 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000008518 lycium barbarum polysaccharide Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 239000001335 perilla frutescens leaf extract Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002040 relaxant effect Effects 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000723353 Chrysanthemum Species 0.000 description 2
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000004531 blood pressure lowering effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 229940030275 epigallocatechin gallate Drugs 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- KINGXFAMZNIVNL-SXQDSXCISA-N safflor yellow A Natural products OC[C@@H]1O[C@H]2[C@H](OC3=C2C(=O)C(=C(O)C=Cc4ccc(O)cc4)C(=O)[C@]3(O)[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)[C@H]1O KINGXFAMZNIVNL-SXQDSXCISA-N 0.000 description 2
- 229940119485 safflower extract Drugs 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000021959 Abnormal metabolism Diseases 0.000 description 1
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- 102100027265 Aldo-keto reductase family 1 member B1 Human genes 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 1
- 206010007191 Capillary fragility Diseases 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 206010007749 Cataract diabetic Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- YZNNBIPIQWYLDM-HSUXUTPPSA-N Fagomine Chemical compound OC[C@H]1NCC[C@@H](O)[C@@H]1O YZNNBIPIQWYLDM-HSUXUTPPSA-N 0.000 description 1
- YZNNBIPIQWYLDM-ZLUOBGJFSA-N Fagomine Natural products OC[C@@H]1NCC[C@H](O)[C@H]1O YZNNBIPIQWYLDM-ZLUOBGJFSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010054787 Haemorrhoidal haemorrhage Diseases 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- AJPXZTKPPINUKN-UHFFFAOYSA-N Isoliensinin Natural products C1=CC(OC)=CC=C1CC1C2=CC(OC=3C(=CC=C(CC4C5=CC(O)=C(OC)C=C5CCN4C)C=3)O)=C(OC)C=C2CCN1C AJPXZTKPPINUKN-UHFFFAOYSA-N 0.000 description 1
- AJPXZTKPPINUKN-FIRIVFDPSA-N Isoliensinine Chemical compound C1=CC(OC)=CC=C1C[C@@H]1C2=CC(OC=3C(=CC=C(C[C@@H]4C5=CC(O)=C(OC)C=C5CCN4C)C=3)O)=C(OC)C=C2CCN1C AJPXZTKPPINUKN-FIRIVFDPSA-N 0.000 description 1
- YZNNBIPIQWYLDM-UHFFFAOYSA-N L-fagomine Natural products OCC1NCCC(O)C1O YZNNBIPIQWYLDM-UHFFFAOYSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- XCUCMLUTCAKSOZ-JSOSNVBQSA-N Liensinine Natural products C([C@@H]1C=2C=C(C(=CC=2CCN1C)OC)OC=1C(O)=CC=C(C=1)C[C@@H]1N(C)CCC=2C=C(C(=CC=21)OC)OC)C1=CC=C(O)C=C1 XCUCMLUTCAKSOZ-JSOSNVBQSA-N 0.000 description 1
- XCUCMLUTCAKSOZ-FIRIVFDPSA-N Liensinine Chemical compound C([C@@H]1C=2C=C(C(=CC=2CCN1C)OC)OC=1C(O)=CC=C(C=1)C[C@H]1N(C)CCC=2C=C(C(=CC=21)OC)OC)C1=CC=C(O)C=C1 XCUCMLUTCAKSOZ-FIRIVFDPSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- MIBATSHDJRIUJK-UHFFFAOYSA-N Neferine Natural products C1=CC(OC)=CC=C1CC1C2=CC(OC=3C(=CC=C(CC4C5=CC(OC)=C(OC)C=C5CCN4C)C=3)O)=C(OC)C=C2CCN1C MIBATSHDJRIUJK-UHFFFAOYSA-N 0.000 description 1
- MIBATSHDJRIUJK-ROJLCIKYSA-N Neferine Chemical compound C1=CC(OC)=CC=C1C[C@@H]1C2=CC(OC=3C(=CC=C(C[C@@H]4C5=CC(OC)=C(OC)C=C5CCN4C)C=3)O)=C(OC)C=C2CCN1C MIBATSHDJRIUJK-ROJLCIKYSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 241000229722 Perilla <angiosperm> Species 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- LUJAXSNNYBCFEE-UHFFFAOYSA-N Quercetin 3,7-dimethyl ether Natural products C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(O)C(O)=C1 LUJAXSNNYBCFEE-UHFFFAOYSA-N 0.000 description 1
- PUTDIROJWHRSJW-UHFFFAOYSA-N Quercitrin Natural products CC1OC(Oc2cc(cc(O)c2O)C3=CC(=O)c4c(O)cc(O)cc4O3)C(O)C(O)C1O PUTDIROJWHRSJW-UHFFFAOYSA-N 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- OXGUCUVFOIWWQJ-XIMSSLRFSA-N acanthophorin B Natural products O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-XIMSSLRFSA-N 0.000 description 1
- 229940039750 aconitine Drugs 0.000 description 1
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000000158 apoptosis inhibitor Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000007025 diabetic cataract Diseases 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- NQYPTLKGQJDGTI-FCVRJVSHSA-N hyperoside Natural products OC[C@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3[C@H]2O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@H]1O NQYPTLKGQJDGTI-FCVRJVSHSA-N 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000011133 lead Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- -1 luteolin glycoside Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 229930189775 mogroside Natural products 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- OEKUVLQNKPXSOY-UHFFFAOYSA-N quercetin 3-O-beta-D-glucopyranosyl(1->3)-alpha-L-rhamnopyranosyl(1->6)-beta-d-galactopyranoside Natural products OC1C(O)C(C(O)C)OC1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OEKUVLQNKPXSOY-UHFFFAOYSA-N 0.000 description 1
- QPHXPNUXTNHJOF-UHFFFAOYSA-N quercetin-7-O-beta-L-rhamnopyranoside Natural products OC1C(O)C(O)C(C)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 QPHXPNUXTNHJOF-UHFFFAOYSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- OXGUCUVFOIWWQJ-HQBVPOQASA-N quercitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-HQBVPOQASA-N 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 108010068815 steroid hormone 7-alpha-hydroxylase Proteins 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/06—Treating tea before extraction; Preparations produced thereby
- A23F3/14—Tea preparations, e.g. using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a safflower perilla heart tea for reducing high blood pressure, high blood sugar and protecting cardiovascular, which comprises the following components in parts by weight: 15-1000 parts of tea, 5-300 parts of safflower, 5-150 parts of perillaseed, 5-150 parts of lotus plumule, 5-300 parts of cassia seed, 2-300 parts of medlar, 2-300 parts of chrysanthemum, 2-150 parts of sophora flower bud, 5-300 parts of hawthorn, 5-300 parts of mulberry leaf and 1-50 parts of momordica grosvenori. The invention also discloses a preparation method of the safflower perilla heart tea for reducing high blood pressure, high blood sugar and protecting the cardiovascular system. The invention adopts the mode of adding seasoning tea, so that patients can take tea for health care every day, the tea is convenient, the side effect of medicines is avoided, and the cost is low.
Description
Technical Field
The invention relates to a safflower perilla heart tea for reducing high blood pressure, high blood sugar and high blood fat and protecting cardiovascular and a preparation method thereof, belonging to the technical field of processing of seasoning tea.
Background
Hypertension, hyperglycemia and hypertriglyceridemia are collectively called hypertension, hyperglycemia and hyperlipidemia, which are the main culprits of cardiovascular and cerebrovascular diseases and seriously harm human health.
Hypertension refers to the condition of higher than normal blood pressure in the circulatory system, usually refers to the increase of systemic arterial blood pressure, and is a common clinical syndrome. Normally, the blood pressure is lower than 140/90 mmhg, and higher than 160/95 mmhg.
Hyperlipidemia refers to the condition of high blood cholesterol or triglyceride or low high-density lipoprotein cholesterol, and is called as dyslipidemia in modern medicine. It is a main factor causing atherosclerosis and is a risk factor for occurrence and development of cardiovascular and cerebrovascular diseases. It is latent in onset and mostly has no clinical symptoms.
Hyperglycemia is the condition that the glucose content in the blood of a body is higher than a normal value and is mostly caused by pathological changes of islet cells existing in the body, and the key of pathological changes is blood sugar metabolic disorder.
The clinical manifestations of hyperglycemia can have dominant symptoms, such as thirst, much drinking water, much urine and emaciation; or may be implicit with no apparent subjective discomfort. The early stage of the hypertension patient can show symptoms of headache, dizziness, tinnitus, palpitation, dim eyesight, inattention, hypomnesis, numbness of hands and feet, fatigue, weakness, easy dysphoria and the like, and the degree of the symptoms is inconsistent with the degree of the increase of the blood pressure; the later stage blood pressure is always kept at a high level, and brain, heart, kidney and other organs are damaged and even fail by accelerating atherosclerotic lesions. Diabetes is a chronic and lifelong disease, is a common disease seriously harming human health, and causes abnormal metabolism of nutrients such as carbohydrate, fat, protein and the like in vivo due to relative or absolute deficiency of insulin. The disease can cause various complications, and can cause systemic diseases when serious, which causes people to be disabled, blindness and even death. The long-term hyperlipidemia easily causes atheromatous plaque to deposit on the blood vessel wall, gradually forms atherosclerosis, leads to the stenosis of the lumen of the blood vessel, and leads to the attenuation and even the interruption of the blood flow. In addition, hyperlipidemia and extensive atherosclerosis can cause hypertension, aggravate fatty liver, induce gallstone and pancreatitis, aggravate cerebral apoplexy and coronary heart disease.
Hypertension, hyperglycemia and hyperlipidemia can exist independently and are often mutually associated, and three types of hypertension, hyperglycemia and hyperlipidemia are integrated in the later stage. Traditional hypoglycemic drugs, antihypertensive drugs and hypolipidemic drugs are easy to resist drugs, the drug types are increased, the dosage is increased, the damage to gastrointestinal tracts and liver and kidney functions of patients after long-term administration is very large, complications are easy to cause, and the life quality of the patients is seriously affected.
According to the national supply and marketing headquarters seasoning tea industry standard GH/T1247-2019, the seasoning tea is a product which is prepared by adding a proper amount of other food raw materials and/or food additives into tea serving as a raw material and is drunk by people in a brewing (soaking or boiling) mode.
Disclosure of Invention
The purpose of the invention is as follows: the present invention is to solve the above problems of the prior art, and it is a first object of the present invention to disclose a safflower perilla heart tea for reducing high blood pressure, high blood sugar and protecting the cardiovascular system. The second purpose of the invention is to disclose a preparation method of safflower perilla heart tea for reducing high blood pressure, high blood sugar and protecting the cardiovascular system.
The technical scheme is as follows: a safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting the cardiovascular system comprises the following components in parts by weight: 15-1000 parts of tea, 5-300 parts of safflower, 5-150 parts of perillaseed, 5-150 parts of lotus plumule, 5-300 parts of cassia seed, 2-300 parts of medlar, 2-300 parts of chrysanthemum, 2-150 parts of sophora flower bud, 5-300 parts of hawthorn, 5-300 parts of mulberry leaf and 1-50 parts of momordica grosvenori.
Further, comprising: 600 parts of tea, 200 parts of safflower, 150 parts of perilla fruit, 150 parts of lotus plumule, 150 parts of cassia seed, 100 parts of medlar, 100 parts of chrysanthemum, 100 parts of sophora flower bud, 150 parts of hawthorn, 150 parts of mulberry leaf and 20 parts of momordica grosvenori.
Furthermore, the tea is any one or more of green tea, white tea, yellow tea, oolong tea, black tea and black tea.
A preparation method of safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular comprises the following steps:
(1) preparing a first filtrate:
(11) weighing the safflower, the perilla fruit, the medlar, the chrysanthemum and the sophora flower bud according to the formula ratio, selecting, screening and removing impurities, cleaning, and placing in an extraction container;
(12) and leaching for the first time:
adding 10-85% V/V ethanol aqueous solution with the volume 5-25 times that of the extraction container, leaching for 4-96 hours at the temperature of 20-75 ℃, filtering, and collecting leaching liquor;
(13) and leaching for the second time:
adding 10-85% V/V ethanol aqueous solution with the volume of 3-20 times that of the extraction container, leaching for 2-72 hours at the temperature of 20-75 ℃, filtering, and collecting leaching liquor;
(14) and leaching for the third time:
adding 10-85% V/V ethanol aqueous solution with the volume of 3-20 times that of the extraction container, leaching for 2-72 hours at the temperature of 20-75 ℃, filtering, and collecting leaching liquor;
(15) combining the leaching liquor obtained in the steps (12) to (14), naturally cooling to normal temperature, standing for 12-96 hours in an environment at 1-10 ℃, collecting supernatant, filtering by using a filter material with a pore size of 0.2-0.5 micrometer, and collecting filtrate to obtain first filtrate;
(2) preparing a second filtrate:
(21) weighing lotus plumule, cassia seed, hawthorn, mulberry leaf and momordica grosvenori according to the formula ratio, selecting, screening and cleaning impurities, and placing the mixture into an extraction container;
(22) and first decoction:
adding 8-30 times of water into the extraction container, soaking for 0.5-4.5 hours, heating to boil, decocting for 0.5-4.5 hours, filtering, and collecting decoction;
(23) and carrying out second decoction:
adding 6-25 times of water by volume into the extraction container, heating to boil, decocting for 0.5-4.5 hours, filtering, and collecting decoction;
(24) and decocting for the third time:
adding 6-25 times of water by volume into the extraction container, heating to boil, decocting for 0.5-4.5 hours, filtering, and collecting decoction;
(25) combining the decoction obtained in the steps (22) to (24), filtering the decoction by a filter screen of 20-300 meshes, centrifuging 300-1200 g to remove fine precipitates, concentrating the supernatant under reduced pressure at 55-95 ℃ and-0.05-0.1 MPa, and concentrating the concentrate into a concentrated solution with the relative density of 1.05-1.25 to obtain a second filtrate;
(3) adding 2-4 times of volume of 90% V/V ethanol aqueous solution into the second filtrate obtained in the step (2) at the temperature of 5-65 ℃, fully stirring, naturally cooling to normal temperature, standing for 12-96 hours in an environment at the temperature of 1-25 ℃, collecting supernatant, filtering the supernatant through a filter material with the filter diameter of 0.2-1.0 micron, and collecting filtrate;
(4) combining the first filtrate obtained in the step (1) and the filtrate obtained in the step (3), fully and uniformly mixing, concentrating under reduced pressure at 55-95 ℃, and-0.05-0.1 MPa, and concentrating the filtrate to the volume of a concentrated solution: the feeding amount of the raw materials is 1 (1-4), and a concentrated solution is obtained, wherein:
the volume of the concentrated solution is measured by milliliter, and the feeding amount of the raw materials is measured by gram;
(5) weighing the picked tea leaves according to the formula ratio, flatly paving the tea leaves in a baking pan with the paving thickness of 0.5-8 cm, and placing the baking pan paved with the tea leaves in a baking oven for ventilation baking at 65-120 ℃ for 0.5-4 hours;
(6) uniformly spraying the concentrated solution obtained in the step (4) on the tea leaves in the baking pan for 1-10 times, and fully stirring to enable the liquid medicine to be completely adsorbed by the tea leaves, wherein:
between two adjacent spraying, continuously baking the tea leaves for 2-6 hours at 65-120 ℃ in a ventilating way, and uniformly turning over the materials every 0.5-2 hours;
(7) and (3) after the concentrated solution obtained in the step (4) is completely and uniformly mixed with the tea leaves in the tray, continuously performing ventilation baking at 65-120 ℃, uniformly turning over the materials every 0.5-2 hours until the tea leaves are dry and slightly pungent, gripping the tea leaves, enabling the tea leaves to be elastic and conglobate, and slightly touching the tea leaves with force to disperse tea leaves particles, thus preparing the safflower Suxin tea for reducing hypertension, hyperglycemia and hyperlipidemia and protecting the cardiovascular system.
Further, the method also comprises the step (8): and (3) adding the safflower perilla heart tea prepared in the step (7) for reducing the three highs and protecting the cardiovascular system into an automatic packaging machine for packaging, and carrying out aluminum-plastic packaging to obtain 1-5000 g of independent packages, thus obtaining the safflower perilla heart tea for reducing the three highs and protecting the cardiovascular system.
Further, ethanol is recovered simultaneously during the concentration under reduced pressure in the step (4).
Further, the tea in the step (5) is prepared by compounding any one or more of green tea, white tea, yellow tea, oolong tea, black tea and black tea.
The invention discloses a compatibility principle of safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular system: tea leaves are used as a main body and a carrier, extracted components of traditional Chinese medicines which are homologous in medicine and food, such as safflower, perilla fruit, lotus plumule and the like are used as auxiliary functional components, and the tea is drunk daily to help consumers to reduce blood sugar, blood fat and blood pressure and protect heart and cerebral vessels. Wherein
Tea leaf: scientific research proves that one of the important reasons for causing the hypertension, the hyperglycemia and the hyperlipidemia is oxidative stress, and the oxidative stress can directly cause micro-vascular damage, islet beta cell apoptosis, hepatocyte steatosis and atherosclerosis. The tea polyphenol which is the main functional component of tea is a pure natural super-strong antioxidant. Research shows that the tea polyphenol has three major mechanisms of inhibiting the generation of free radicals, directly eliminating the free radicals and activating a human body to eliminate the free radical system to play an antioxidation role, and is mainly reflected in the aspects of regulating blood fat, preventing cardiovascular and cerebrovascular diseases, regulating immunologic function, delaying aging and the like. The tea drink is helpful for preventing lipid peroxidation caused by hyperlipemia oxygen free radicals, and atherosclerosis. The tea polyphenol can reduce total cholesterol and triglyceride in serum by about 19% and increase the ratio of high density lipoprotein to low density lipoprotein, and the difference between the ratio before and after experiment is 36.1%, which indicates that the tea polyphenol is helpful for preventing hyperlipidemia and atherosclerosis. The tea drinking can eliminate the excessive heavy metal ions in the body, and researches show that tea polyphenol molecules can be complexed with the heavy metal ions such as lead, tin, iron, calcium and the like to form a cyclic chelate to generate precipitation, thereby eliminating the excessive heavy metal ions in the body. The excessive iron in the body of a patient with coronary heart disease can be generated, the heart cells are damaged by free radicals caused by the iron, and if the excessive iron can be removed in time, the heart can be protected. The tea polyphenol has strong coordination ability, can coordinate with iron, and is discharged out of body in the form of complex, thereby protecting heart.
Researches show that epigallocatechin gallate (EGCG) in tea not only can obviously improve insulin activity, but also can inhibit lipase activity by activating an adenylate activated protein kinase signal, and protect islet cell signaling and lipid regulation, thereby preventing type 2 diabetes. The tea polysaccharide can eliminate excessive free radicals generated in vivo by enhancing the antioxidant function of organism, thereby protecting islet cells from free radical invasion. The tea can reduce the generation of free radicals in mice caused by type 2 diabetes by improving the activity of free radical scavenging enzyme, thus relieving the damage of islet cells to a great extent, being beneficial to reducing blood sugar and improving glycolipid metabolism. Some components in the tea pigment also have the effects of resisting oxidation and removing free radicals, so that the oxidation damage to lymphocytes is reduced after the diabetic drinks the tea, and the symptoms of the diabetic can be relieved; in addition, some scholars think that tea pigment improves systemic microcirculation and tissue metabolism level by regulating blood viscosity, thereby improving the function of insulin cells and reducing blood sugar.
Safflower: safflower is the essential drug for dredging blood vessels, relieving swelling and pain, activating blood and dissolving stasis, and stimulating the menstrual flow and relieving pain, and belongs to the drugs for breaking blood and dissolving stasis. The main chemical components are safflower quinonoid glycoside, neosafflower glycoside, safflower yellow, and safflower oil. It is one of the most widely used blood-activating and stasis-resolving medicaments. In more than ten years, the research has been greatly developed, and the safflower yellow (HSYA) can antagonize the specific binding of PAF and rabbit platelets and inhibit PAF-induced blood cell aggregation; the blood pressure of the rabbits can be effectively reduced, and the average value of the reduction of the diastolic pressure and the systolic pressure is about 10-30 mmHg. In recent years, studies on the effect of safflower extract on gene regulation have been increasing. Research shows that the safflower extract can inhibit the rapid proliferation and growth of Vascular Smooth Muscle Cells (VSMC) of rats and reduce the activity of the VSMC NF-KB, thereby treating vascular proliferative diseases such as hypertension, coronary atherosclerotic heart disease, restenosis after angioplasty and the like; the safflower is probably related to the inhibition of the expression of a pro-apoptosis agent Caspase-3 and the enhancement of the expression of an apoptosis inhibitor Bcl-2 to the cerebral ischemia-reperfusion injury, namely the safflower realizes the anti-apoptosis effect by influencing the expression of an apoptosis regulating gene and plays a role in protecting the myocardial and cerebral ischemia-reperfusion injury.
And (3) Perilla seed: modern researches show that perillaseed has the effects of regulating blood fat and resisting lipid peroxidation, and can obviously reduce the contents of TC, TG and LDL-C, MDA in serum and increase the contents of HDL-C and SOD activity in serum. Perilla seed oil is rich in unsaturated fatty acids, especially alpha-linolenic acid, and has pharmacological effects of reducing blood lipid, lowering blood pressure, resisting thrombi, resisting cancer, resisting inflammation and oxidation. Experiments show that perilla seed oil can obviously reduce the content of Total Cholesterol (TC) and Triacylglycerol (TG) in plasma of a rat with hyperlipidemia and improve the content of high-density lipoprotein cholesterol (HDL-C), and the perilla seed oil with high dose can reduce the lipid deposition in the liver of the rat with hyperlipidemia, prevent the occurrence of fatty liver and has the function of resisting hypertension.
Lotus plumule: has effects in clearing away heart-fire, tranquilizing mind, regulating functions of heart and kidney, arresting seminal emission, and stopping bleeding. Modern researches show that the main components of the lotus plumule comprise alkaloids such as liensinine, isoliensinine and neferine, and flavonoids such as luteolin glycoside, hyperoside and rutin. Has effects in lowering blood pressure, resisting arrhythmia, inhibiting platelet aggregation, resisting oxidation, scavenging active free radicals, resisting myocardial ischemia, relaxing smooth muscle, tonifying heart, resisting cancer, protecting cerebral ischemia injury, improving acute lung injury and pulmonary fibrosis, inhibiting central nervous system, and lowering blood sugar. Active components and action targets in the lotus plumule are searched through TCMSP and BATMAN-TCM databases, effective targets for treating hypertension are searched in TTD, CTD and DRUGBANK databases, and 25 components and 59 key targets are screened out from the lotus plumule, which relates to 10 main signal paths; the lotus plumule is proved to be capable of synergistically regulating and controlling blood pressure through multiple paths and improving emotional symptoms of hypertension patients. Clinical research shows that hypertension patients can reduce indexes such as carotid artery IMT, ba-PWV and the like by adding lotus plumule intervention treatment, and the lotus plumule has an anti-arteriosclerosis effect, and the effects are probably related to the influence of the lotus plumule intervention treatment on the expression level of inflammatory factors and MMP-9.
Cassia seed: sweet, bitter, salty and slightly cold in nature, has the effects of clearing heat, improving eyesight, loosening bowel to relieve constipation, and is used for treating conjunctival congestion, swelling and pain, photophobia, lacrimation, headache, vertigo, dim eyesight, habitual constipation, etc. Modern medical research considers that cassia seed has the effects of reducing blood pressure, regulating lipid, protecting liver, improving renal function and the like, and is a representative medicine for treating cardiovascular and cerebrovascular diseases, hyperlipidemia and constipation in traditional Chinese medicine. The cassia seed is ground into powder, is soaked in boiled water for meal and is taken orally, 12 cases of primary hypercholesterolemia are treated, the treatment lasts for 30 days, various indexes of blood fat are obviously reduced after the cassia seed is treated, the weight of a patient is also reduced, abdominal distension and abdominal pain disappear, and the symptoms of fatty liver are relieved. When 36 patients with coronary heart disease (9 patients with hyperlipidemia) are treated with semen Cassiae and fructus crataegi for 1 month, the blood lipid level of the patients is remarkably reduced, and the symptoms of angina pectoris are also remarkably improved. 43 cases of patients with primary hypertension are taken with cassia seed powder, and the total effective rate of lowering blood pressure is 93.02%. Experiments show that the antihypertensive effect of cassia seed is probably related to the excitation of cholinergic nerves and the excitation of peripheral M receptors. The extract of the cassia seed is drenched into Japanese big ear white rabbits of models of hyperlipemia caused by high-fat feed, and the serum cholesterol, triglyceride and low-density lipoprotein content of the model animals can be obviously reduced after the extract is continuously administrated for 14 and 28 days; the semen cassiae ethanol extract can also obviously reduce the MDA content of the serum of a model animal, improve the SOD activity and relieve the pathological damage of liver cells; when the semen cassiae extract is used for treating the fatty liver model rat, the activity of liver enzyme of the model animal can be obviously reduced, and the degree of fatty degeneration of liver cells is obviously reduced.
Medlar: sweet taste, neutral nature, entering liver, kidney and lung meridians, moistening qi and ascending and descending. Has effects in nourishing liver, improving eyesight, moistening lung, promoting salivation, invigorating qi, replenishing vital essence, nourishing liver and kidney, resisting aging, quenching thirst, warming body, and resisting tumor. Fructus Lycii is rich in carotene and vitamin A, B1、B2C, calcium, iron and other nutrients necessary for eye health care, so the eye drops are good at improving eyesight and are commonly called as 'eyesight improving eyes'. Fructus Lycii has effects of lowering blood pressure, blood lipid and blood sugar, preventing atherosclerosis, protecting liver, inhibiting fatty liver, and promoting liver cell regeneration. The medlar can effectively reduce the content of triglyceride and cholesterol in the serum of a rat with hyperlipidemia, has obvious function of reducing the blood lipid and regulates the lipid metabolism. Researches show that the functional component of the medlar, namely medlar polysaccharide 3b, has the competitive inhibition effect with glucose absorption, namely the medlar polysaccharide can delay the glucose absorption and reduce the glucose absorption by combining with glucose absorption sitesLow postprandial blood glucose. In addition, the lycium barbarum polysaccharide obviously enhances the activity of SOD (superoxide dismutase) in damaged islet cells, improves the oxidation resistance of the islet cells, lightens the damage of peroxide to the cells, and reduces the generation amount of malonaldehyde, which shows that the lycium barbarum polysaccharide has a certain protection effect on the islet cells. The lycium barbarum polysaccharide can also reduce the systolic blood pressure and the diastolic blood pressure of rats; reduce the content of malondialdehyde and endothelin in blood plasma and blood vessel, increase the release of calcitonin gene-related peptide, and prevent hypertension.
Chrysanthemum: according to the record of compendium of materia medica, chrysanthemum is indicated for wind-syndrome and dizziness, improving eyesight and dispelling wind, searching liver qi, benefiting blood and moistening face. Modern pharmacological research shows that chrysanthemum has a plurality of pharmacological effects of resisting bacteria, inflammation and oxidation, relaxing blood vessels, reducing blood fat, resisting tumors, expelling lead and the like. The flavonoids of flos Chrysanthemi have effects in enhancing resistance of capillary vessel, inhibiting capillary permeability, resisting inflammation, scavenging free radicals and oxidation, increasing coronary blood flow, resisting arrhythmia induced by aconitine and chloroform, and antagonizing Ca2+The internal flow of the medicine can improve the contractility of cardiac muscle cells, and has obvious effects of relaxing blood vessels, reducing blood pressure and blood fat. The water decoction and alcohol precipitation preparation of chrysanthemum has the function of increasing the flow of coronary artery of the heart of an experimental animal and can improve the ST-segment depression of ischemic electrocardiogram caused by electrically stimulating central nerve. Can also increase coronary flow and myocardial oxygen consumption for isolated heart of experimental coronary arteriosclerosis animal. The experimental result shows that the chrysanthemum aqueous extract can obviously inhibit lipid peroxidation caused by D-galactose, and reduce the content of Malondialdehyde (MDA) and the activity of monoamine oxidase (MAO) in blood; increasing the activity of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) in blood.
And (3) flos sophorae immaturus: the Huai Hua Xin is also called as the Huai Hua, bitter in property and slightly cold in property, and enters liver and large intestine meridians. It is called from Chinese pharmacopoeia for cooling blood to stop bleeding, clearing liver-fire and purging fire, and can be used for hematochezia, hemorrhoidal bleeding, bloody dysentery, metrorrhagia and metrostaxis, hematemesis, epistaxis, liver heat with reddish eyes, headache and vertigo. The sophora flower liquid has a transient but obvious blood pressure reducing effect and has a slight exciting effect on cardiac muscle. The main component rutin has vitamin P-like effect, can reduce abnormal permeability and fragility of capillary, and can be used for treating and preventing hypertension, cerebral hemorrhage, etc., and maintaining blood vessel resistance, etc.; the quercetin contained in the product has effects of lowering blood pressure, enhancing capillary resistance, reducing capillary fragility, dilating coronary artery, and increasing coronary blood flow. Rutin which is the main component of the sophora flower has the function of removing fat from liver infiltrated by fat, the fat removing effect is more obvious when the rutin is used together with glutathione, and the contained quercetin also has the function of reducing blood fat; the genistein contained in the composition has the effect of reducing cholesterol and triglyceride in blood of experimental hyperlipaemia rats, and has particularly obvious effect on the latter. In addition, rutin has aldose reductase inhibiting effect, and its inhibition rate at 105mol/L concentration is 95%, which is beneficial for treating diabetic cataract.
Hawthorn fruit: slightly warm in nature, sour and sweet in taste. It enters spleen, stomach and liver meridians. The hawthorn contains various active ingredients such as ursolic acid, flavonoid, saponin, sugar, organic acid, pigment and the like, has the effects of promoting digestion, removing food retention, promoting qi circulation and removing blood stasis, has the best digestion effect on human bodies, and is particularly suitable for spleen and stomach weakness, indigestion and greasy regurgitation. Haw is good at moving qi of stomach and intestine, and indicated for food retention, stomach and intestine and abdominal distention. It is used clinically in treating indigestion and postpartum abdominal pain due to blood stasis. In recent years, the hawthorn has the effects of reducing blood pressure, reducing blood fat, improving myocardial ischemia, reducing cholesterol, resisting lipid peroxidation and the like, and has good effect on treating cardiovascular and cerebrovascular diseases. The total extract or total saponin of fructus crataegi can cause blood pressure decrease of experimental mouse, rabbit and cat. The small dosage of hawthorn fluid extract, flavone or hydrolysate is injected into anesthetized cats, anesthetized rabbits or anesthetized mice, and has slow and lasting blood pressure reduction effect, and the blood pressure reduction principle is mainly based on peripheral blood vessel expansion. The hawthorn has an inhibition effect on a rate-limiting enzyme (HMG-CoA reductase) for synthesizing the cholesterol in liver cell microsomes and small intestinal mucosa, but has no obvious influence on a rate-limiting enzyme (7 alpha-hydroxylase) for decomposing the cholesterol in the liver, so that the effect of regulating lipid metabolism by the hawthorn is generated by inhibiting the synthesis of the cholesterol in the liver and increasing the level of LDLR to promote the cholesterol in plasma to be absorbed into the liver. The hawthorn and hawthorn flavone can obviously reduce the content of serum and liver Malondialdehyde (MDA), enhance the activity of erythrocyte and liver superoxide dismutase (SOD), simultaneously increase the activity of whole blood glutathione reductase (GSH-Px), and have therapeutic effect on experimental atherosclerosis. Chrysanthemum, honeysuckle and hawthorn 5: 5: the 4-formula tea drink can be used for treating patients with hyperlipidemia, hypertension and arteriosclerosis with abnormal hemorheology, and the total effective rate is 95%.
Mulberry leaf: meanwhile, the tea has the miraculous effect of reducing high blood pressure, high blood sugar and high blood sugar. Researches find that the mulberry leaves and the mulberry leaf tea rich in gamma-aminobutyric acid have definite blood pressure lowering effect and no side effect, and meanwhile, rutin, quercetin and quercitrin in the mulberry leaves can increase the contractility and output in vitro and in the frog heart and reduce the heart rate. Rutin in folium Mori can cause vasoconstriction of toad lower limbs and rabbit ear, quercetin can dilate coronary blood vessel, and improve myocardial circulation. The folium Mori contains gamma-aminobutyric acid, rutin, and quercetin, and has blood pressure lowering effect. The gamma-aminobutyric acid in mulberry leaves is a nerve transmission substance, can promote the metabolism of brain tissues and restore the function of brain cells, and simultaneously can improve the blood flow of the brain, enhance the activity of angiotensin I converting enzyme I and promote the reduction of blood pressure. Researches find that mulberry leaves generally contain rich gamma-aminobutyric acid components, and the content of the gamma-aminobutyric acid can be obviously increased by technologies such as microbial fermentation and the like. Folium Mori has effects of inhibiting fatty liver formation, reducing serum fat and inhibiting atherosclerosis formation. The active ingredients include Deoxynojirimycin (DNJ), phytosterol, flavonoids, polysaccharides, etc. The mulberry leaves contain flavonoid components for strengthening capillary vessels and reducing blood viscosity, and the mulberry leaves contain components for resisting LDL-lipoprotein oxidation in vivo, so that the mulberry leaves have the effects of reducing weight, improving hyperlipidemia and preventing myocardial infarction and cerebral hemorrhage. Alkaloids and polysaccharides are the main hypoglycemic components in mulberry leaves. The hypoglycemic effect of mulberry leaves is realized through two ways: the method has the advantages that 1-Deoxynojirimycin (DNJ) serving as alkaloid has an inhibitory effect on activity of disaccharide degrading enzymes, so that absorption of disaccharide by small intestine is inhibited, and high peak value of blood sugar after eating is reduced; secondly, cell secretion of insulin is promoted through mulberry leaf alkaloid (fagomine) and mulberry leaf polysaccharide, and the insulin can promote the utilization of sugar by cells, the synthesis of hepatic glycogen and the improvement of glycometabolism, so that the effect of reducing blood sugar is finally achieved.
Momordica grosvenori: the high sweet taste is mainly used for replacing a sweetener, and the momordica grosvenori has increasingly attracted attention in recent years due to the effects of scavenging free radicals, resisting oxidation, regulating blood sugar and regulating immunity. Researches find that the momordica grosvenori powder and the extract thereof have no influence on blood sugar and sugar tolerance of normal mice, but have obvious blood sugar reducing effect on alloxan diabetic mice, have prevention and treatment effect on abnormal rise of serum cholesterol and serum triacylglycerol in the diabetic mice, can improve the content of serum high-density lipoprotein cholesterol, enable the blood fat level of organisms to tend to be normal, and prevent lipid metabolism disorder caused by diabetes. The fructus Siraitiae Grosvenorii flavone can inhibit ADP-induced platelet aggregation in rat, significantly reduce cholesterol and triacylglycerol content in hypercholesterolemic mouse, increase high density lipoprotein cholesterol level, prolong blood coagulation time of mouse, and has certain pharmacological effects of promoting blood circulation and removing blood stasis such as anticoagulation. Mogroside has protective effect on liver injury and fatty liver, and can effectively reduce AST and ALT activity in blood serum, improve pathological change degree of liver tissue, reduce MDA content of liver tissue homogenate, and increase SOD activity.
Has the advantages that: compared with the prior art, the invention has the beneficial effects that: the invention adopts the mode of adding seasoning tea, so that patients can take tea for health care every day, the tea is convenient, the side effect of medicines is avoided, and the cost is low.
The specific implementation mode is as follows:
the following describes in detail specific embodiments of the present invention.
Detailed description of the preferred embodiment 1
A safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting the cardiovascular system comprises the following components in parts by weight:
600 parts of tea, 200 parts of safflower, 150 parts of perilla fruit, 150 parts of lotus plumule, 150 parts of cassia seed, 100 parts of medlar, 100 parts of chrysanthemum, 100 parts of sophora flower bud, 150 parts of hawthorn, 150 parts of mulberry leaf and 20 parts of momordica grosvenori.
Further, the tea leaves are oolong tea.
A preparation method of safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular comprises the following steps:
(1) preparing a first filtrate:
(11) weighing the safflower, the perilla fruit, the medlar, the chrysanthemum and the sophora flower bud according to the formula ratio, selecting, screening and removing impurities, cleaning, and placing in an extraction container;
(12) and leaching for the first time:
adding 15 times volume of 60% V/V ethanol water solution into the extraction container, leaching for 50 hours at 35 ℃, filtering, and collecting leaching liquor;
(13) and leaching for the second time:
adding 60% V/V ethanol water solution with volume 12 times of the extraction container, leaching at 55 deg.C for 36 hr, filtering, and collecting leaching solution;
(14) and leaching for the third time:
adding 40% V/V ethanol water solution with volume 12 times of the extraction container, leaching at 50 deg.C for 36 hr, filtering, and collecting leaching solution;
(15) combining the leaching liquor obtained in the steps (12) to (14), naturally cooling to normal temperature, standing in an environment of 5 ℃ for 48 hours, collecting supernatant, filtering by using a filter material with a pore size of 0.4 micron, and collecting filtrate to obtain first filtrate;
(2) preparing a second filtrate:
(21) weighing lotus plumule, cassia seed, hawthorn, mulberry leaf and momordica grosvenori according to the formula ratio, selecting, screening and cleaning impurities, and placing the mixture into an extraction container;
(22) and first decoction:
adding water with the volume 20 times that of the extraction container, soaking for 3 hours, heating to boil, decocting for 3 hours, filtering, and collecting decoction;
(23) and carrying out second decoction:
adding 10 times of water into the extraction container, heating to boil, decocting for 2 hours, filtering, and collecting decoction;
(24) and decocting for the third time:
adding 15 times of water into the extraction container, heating to boil, decocting for 3 hours, filtering, and collecting decoction;
(25) mixing the decoctions obtained in the steps (22) to (24), filtering by a 100-mesh filter screen, centrifuging by 600g to remove fine precipitates, concentrating the supernatant under reduced pressure at 70 ℃ and-0.07 MPa, and concentrating to obtain a concentrated solution with the relative density of 1.15 to obtain a second filtrate;
(3) adding 90% V/V ethanol water solution with the volume of 3 times of that of the second filtrate obtained in the step (2) into the second filtrate at 40 ℃, fully stirring the mixture, naturally cooling the mixture to the normal temperature, standing the mixture in an environment at 15 ℃ for 48 hours, collecting supernatant, filtering the supernatant by using a filter material with the filter diameter of 0.5 micron, and collecting filtrate;
(4) combining the first filtrate obtained in the step (1) and the filtrate obtained in the step (3), fully and uniformly mixing, concentrating under reduced pressure at 75 ℃ and-0.07 MPa, and concentrating the filtrate to the volume of a concentrated solution: the feeding amount of the raw materials is 1:2, and a concentrated solution is obtained, wherein:
the volume of the concentrated solution is measured by milliliter, and the feeding amount of the raw materials is measured by gram;
(5) weighing the picked tea leaves according to the formula ratio, flatly paving the tea leaves in a baking pan with the paving thickness of 4 cm, and placing the baking pan paved with the tea leaves in an oven for baking for 3 hours in a ventilation mode at the temperature of 80 ℃;
(6) uniformly spraying the concentrated solution obtained in the step (4) onto the tea leaves in the baking pan for 5 times, and fully stirring to enable the liquid medicine to be completely adsorbed by the tea leaves, wherein:
continuously baking the tea leaves at 65 ℃ for 6 hours in a ventilating way between two adjacent spraying processes, and uniformly turning over the materials every 2 hours;
(7) and (3) after the concentrated solution obtained in the step (4) is completely and uniformly mixed with the tea leaves in the tray, continuously carrying out ventilation baking at the temperature of 80 ℃, uniformly turning over the materials every 1 hour until the tea leaves are dry and have slight sense of thorny, gripping the tea leaves, enabling the tea leaves to have elasticity and be conglobate, and slightly forcibly touching the tea leaves to enable the tea leaves to be scattered, thus preparing the safflower Suxin tea for reducing hypertension, hyperglycemia and hyperlipidemia and protecting the cardiovascular system.
Further, the method also comprises the step (8): and (3) adding the safflower perilla heart tea prepared in the step (7) for reducing the three highs and protecting the cardiovascular system into an automatic packaging machine for packaging, and packaging the safflower perilla heart tea into 100 g of independent packages by aluminum-plastic packaging to obtain the safflower perilla heart tea which is independently packaged and used for reducing the three highs and protecting the cardiovascular system.
Further, ethanol is recovered simultaneously during the concentration under reduced pressure in the step (4).
Further, the tea leaves in the step (5) are oolong tea.
Specific example 2
A safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting the cardiovascular system comprises the following components in parts by weight: 15 parts of tea, 5 parts of safflower, 5 parts of perilla fruit, 5 parts of lotus plumule, 5 parts of cassia seed, 2 parts of medlar, 2 parts of chrysanthemum, 2 parts of sophora flower bud, 5 parts of hawthorn, 5 parts of mulberry leaf and 1 part of momordica grosvenori. Further, the tea leaves are green tea.
A preparation method of safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular comprises the following steps:
(1) preparing a first filtrate:
(11) weighing the safflower, the perilla fruit, the medlar, the chrysanthemum and the sophora flower bud according to the formula ratio, selecting, screening and removing impurities, cleaning, and placing in an extraction container;
(12) and leaching for the first time:
adding 10% V/V ethanol aqueous solution with volume 5 times of the extraction container, leaching for 96 hours at 20 ℃, filtering, and collecting the leaching liquor;
(13) and leaching for the second time:
adding 85% V/V ethanol water solution with volume 3 times of the extraction container, leaching for 72 hours at 20 ℃, filtering, and collecting leaching liquor;
(14) and leaching for the third time:
adding 10% V/V ethanol water solution with volume 3 times of the extraction container, leaching for 72 hours at 20 ℃, filtering, and collecting leaching liquor;
(15) combining the leaching liquor obtained in the steps (12) to (14), naturally cooling to normal temperature, standing in an environment at 1 ℃ for 96 hours, collecting supernatant, filtering by using a filter material with a pore size of 0.2 micron, and collecting filtrate to obtain first filtrate;
(2) preparing a second filtrate:
(21) weighing lotus plumule, cassia seed, hawthorn, mulberry leaf and momordica grosvenori according to the formula ratio, selecting, screening and cleaning impurities, and placing the mixture into an extraction container;
(22) and first decoction:
adding 8 times of water into the extraction container, soaking for 0.5 hr, heating to boil, decocting for 0.5 hr, filtering, and collecting decoction;
(23) and carrying out second decoction:
adding 6 times of water into the extraction container, heating to boil, decocting for 0.5 hr, filtering, and collecting decoction;
(24) and decocting for the third time:
adding 6 times of water into the extraction container, heating to boil, decocting for 0.5 hr, filtering, and collecting decoction;
(25) mixing the decoctions obtained in the steps (22) to (24), filtering by a 20-mesh filter screen, centrifuging by 300g to remove fine precipitates, concentrating the supernatant under reduced pressure at 55 ℃ and-0.1 MPa, and concentrating to obtain a concentrated solution with the relative density of 1.05, thereby obtaining a second filtrate;
(3) adding 90% V/V ethanol water solution with 2 times volume amount into the second filtrate obtained in the step (2) at the temperature of 5 ℃, fully stirring, naturally cooling to normal temperature, standing for 96 hours at the temperature of 1 ℃, collecting supernatant, filtering the supernatant by using a 0.2 micron filter material, and collecting filtrate;
(4) combining the first filtrate obtained in the step (1) and the filtrate obtained in the step (3), fully and uniformly mixing, concentrating under reduced pressure at 55 ℃ and-0.1 MPa, and concentrating the filtrate to the volume of a concentrated solution: the feeding amount of the raw materials is 1:1, and a concentrated solution is obtained, wherein:
the volume of the concentrated solution is measured by milliliter, and the feeding amount of the raw materials is measured by gram;
(5) weighing the picked tea leaves according to the formula ratio, flatly paving the tea leaves in a baking pan with the paving thickness of 0.5 cm, and placing the baking pan paved with the tea leaves in a baking oven for ventilation baking for 0.5 hour at 65 ℃;
(6) uniformly spraying the concentrated solution obtained in the step (4) onto the tea leaves in the baking pan for 1 time, and fully stirring to enable the concentrated solution to be completely adsorbed by the tea leaves;
(7) and (3) after the concentrated solution obtained in the step (4) is completely and uniformly mixed with the tea leaves in the tray, continuously carrying out ventilation baking at 65 ℃, uniformly turning over the materials every 0.5 hour until the tea leaves are dry and slightly pungent, gripping the tea leaves, enabling the tea leaves to be elastic and to be conglobated, and slightly forcibly touching the tea leaves to enable the tea leaves to be scattered, thus preparing the safflower Suxin tea for reducing hypertension, hyperglycemia and hyperlipidemia and protecting the cardiovascular system.
Further, the method also comprises the step (8): and (3) adding the safflower perilla heart tea prepared in the step (7) for reducing the three highs and protecting the cardiovascular system into an automatic packaging machine for packaging, and carrying out aluminum-plastic packaging to obtain 1 g of independent packages, namely the safflower perilla heart tea for reducing the three highs and protecting the cardiovascular system.
Further, ethanol is recovered simultaneously during the concentration under reduced pressure in the step (4).
Further, the tea leaves in the step (5) are green tea.
Specific example 3
A safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting the cardiovascular system comprises the following components in parts by weight: 1000 parts of tea, 300 parts of safflower, 100 parts of perilla fruit, 100 parts of lotus plumule, 300 parts of cassia seed, 300 parts of medlar, 300 parts of chrysanthemum, 150 parts of sophora flower bud, 300 parts of hawthorn, 300 parts of mulberry leaf and 50 parts of momordica grosvenori.
Further, the tea leaves are white tea.
A preparation method of safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular comprises the following steps:
(1) preparing a first filtrate:
(11) weighing the safflower, the perilla fruit, the medlar, the chrysanthemum and the sophora flower bud according to the formula ratio, selecting, screening and removing impurities, cleaning, and placing in an extraction container;
(12) and leaching for the first time:
adding 25 times volume of 85% V/V ethanol water solution into the extraction container, leaching at 75 deg.C for 4 hr, filtering, and collecting leaching solution;
(13) and leaching for the second time:
adding 10% V/V ethanol water solution with 20 times volume into the extraction container, leaching for 2 hours at 75 ℃, filtering, and collecting leaching liquor;
(14) and leaching for the third time:
adding 85% V/V ethanol water solution with 20 times volume into the extraction container, leaching at 75 deg.C for 2 hr, filtering, and collecting leaching solution;
(15) combining the leaching liquor obtained in the steps (12) to (14), naturally cooling to normal temperature, standing in a 10 ℃ environment for 12 hours, collecting supernatant, filtering by using a filter material with a pore size of 0.5 micron, and collecting filtrate to obtain first filtrate;
(2) preparing a second filtrate:
(21) weighing lotus plumule, cassia seed, hawthorn, mulberry leaf and momordica grosvenori according to the formula ratio, selecting, screening and cleaning impurities, and placing the mixture into an extraction container;
(22) and first decoction:
adding 30 times of water into the extraction container, soaking for 4.5 hours, heating to boil, decocting for 4.5 hours, filtering, and collecting decoction;
(23) and carrying out second decoction:
adding 25 times of water into the extraction container, heating to boil, decocting for 4.5 hours, filtering, and collecting decoction;
(24) and decocting for the third time:
adding 25 times of water into the extraction container, heating to boil, decocting for 4.5 hours, filtering, and collecting decoction;
(25) combining the decoction obtained in the steps (22) to (24), filtering the decoction by a 300-mesh filter screen, centrifuging 1200g of the filtrate to remove fine precipitates, concentrating the supernatant under reduced pressure at 95 ℃ and-0.05 MPa, and concentrating the concentrate to obtain a concentrated solution with the relative density of 1.25, thereby obtaining a second filtrate;
(3) adding 90% V/V ethanol water solution with 4 times volume amount into the second filtrate obtained in the step (2) at 65 ℃, fully stirring, naturally cooling to normal temperature, standing in an environment at 25 ℃ for 12 hours, collecting supernatant, filtering the supernatant by using a filter material with the filter diameter of 1.0 micron, and collecting filtrate;
(4) combining the first filtrate obtained in the step (1) and the filtrate obtained in the step (3), fully and uniformly mixing, concentrating under reduced pressure at 95 ℃ and-0.05 MPa, and concentrating the filtrate to the volume of a concentrated solution: the feeding amount of the raw materials is 1:4, and a concentrated solution is obtained, wherein:
the volume of the concentrated solution is measured by milliliter, and the feeding amount of the raw materials is measured by gram;
(5) weighing the picked tea leaves according to the formula ratio, flatly paving the tea leaves in a baking pan with the paving thickness of 8 cm, and placing the baking pan paved with the tea leaves in an oven for 4 hours at 120 ℃ for ventilation baking;
(6) uniformly spraying the concentrated solution obtained in the step (4) on the tea leaves in the baking pan for 10 times, and fully stirring to ensure that the liquid medicine is completely adsorbed by the tea leaves, wherein:
between two adjacent spraying, continuously baking the tea leaves for 2 hours at 120 ℃ in a ventilating way, and uniformly turning over the materials every 0.5 hour;
(7) and (3) after the concentrated solution obtained in the step (4) is completely and uniformly mixed with the tea leaves in the tray, continuously carrying out ventilation baking at the temperature of 120 ℃, uniformly turning over the materials every 0.5 hour until the tea leaves are dry and have slight sense of thorny, gripping the tea leaves, enabling the tea leaves to have elasticity, forming a cluster, and slightly forcibly touching the tea leaves to enable the tea leaves to be scattered, thus preparing the safflower Suxin tea for reducing hypertension, hyperglycemia and hyperlipidemia and protecting the cardiovascular system.
And (8) adding the safflower perilla heart tea prepared in the step (7) for reducing the three-high blood pressure and protecting the cardiovascular system into an automatic packaging machine for packaging, and packaging 5000 g of independent packages by aluminum-plastic packaging to obtain the safflower perilla heart tea which is independently packaged and used for reducing the three-high blood pressure and protecting the cardiovascular system.
Further, ethanol is recovered simultaneously during the concentration under reduced pressure in the step (4).
Further, the tea leaves in the step (5) are white tea.
Examples 4 to 7
The same as example 1, except that the tea leaves were selected:
the embodiments of the present invention have been described in detail. However, the present invention is not limited to the above-described embodiments, and various changes can be made within the knowledge of those skilled in the art without departing from the spirit of the present invention.
Claims (7)
1. The safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting the cardiovascular system is characterized by comprising the following components in parts by weight: 15-1000 parts of tea, 5-300 parts of safflower, 5-150 parts of perillaseed, 5-150 parts of lotus plumule, 5-300 parts of cassia seed, 2-300 parts of medlar, 2-300 parts of chrysanthemum, 2-150 parts of sophora flower bud, 5-300 parts of hawthorn, 5-300 parts of mulberry leaf and 1-50 parts of momordica grosvenori.
2. The safflower perilla heart tea for reducing high blood pressure, high blood sugar and protecting the cardiovascular system as claimed in claim 1, which comprises: 600 parts of tea, 200 parts of safflower, 150 parts of perilla fruit, 150 parts of lotus plumule, 150 parts of cassia seed, 100 parts of medlar, 100 parts of chrysanthemum, 100 parts of sophora flower bud, 150 parts of hawthorn, 150 parts of mulberry leaf and 20 parts of momordica grosvenori.
3. The safflower perilla heart tea for reducing high blood pressure, high blood sugar and protecting the cardiovascular system as claimed in claim 2, wherein the tea is any one or more of green tea, white tea, yellow tea, oolong tea, black tea and black tea.
4. A preparation method of the safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting the cardiovascular system of any one of claims 1 to 3 is characterized by comprising the following steps:
(1) preparing a first filtrate:
(11) weighing the safflower, the perilla fruit, the medlar, the chrysanthemum and the sophora flower bud according to the formula ratio, selecting, screening and removing impurities, cleaning, and placing in an extraction container;
(12) and leaching for the first time:
adding 10-85% V/V ethanol aqueous solution with the volume 5-25 times that of the extraction container, leaching for 4-96 hours at the temperature of 20-75 ℃, filtering, and collecting leaching liquor;
(13) and leaching for the second time:
adding 10-85% V/V ethanol aqueous solution with the volume of 3-20 times that of the extraction container, leaching for 2-72 hours at the temperature of 20-75 ℃, filtering, and collecting leaching liquor;
(14) and leaching for the third time:
adding 10-85% V/V ethanol aqueous solution with the volume of 3-20 times that of the extraction container, leaching for 2-72 hours at the temperature of 20-75 ℃, filtering, and collecting leaching liquor;
(15) combining the leaching liquor obtained in the steps (12) to (14), naturally cooling to normal temperature, standing for 12-96 hours in an environment at 1-10 ℃, collecting supernatant, filtering by using a filter material with a pore size of 0.2-0.5 micrometer, and collecting filtrate to obtain first filtrate;
(2) preparing a second filtrate:
(21) weighing lotus plumule, cassia seed, hawthorn, mulberry leaf and momordica grosvenori according to the formula ratio, selecting, screening and cleaning impurities, and placing the mixture into an extraction container;
(22) and first decoction:
adding 8-30 times of water into the extraction container, soaking for 0.5-4.5 hours, heating to boil, decocting for 0.5-4.5 hours, filtering, and collecting decoction;
(23) and carrying out second decoction:
adding 6-25 times of water by volume into the extraction container, heating to boil, decocting for 0.5-4.5 hours, filtering, and collecting decoction;
(24) and decocting for the third time:
adding 6-25 times of water by volume into the extraction container, heating to boil, decocting for 0.5-4.5 hours, filtering, and collecting decoction;
(25) combining the decoction obtained in the steps (22) to (24), filtering the decoction by a filter screen of 20-300 meshes, centrifuging 300-1200 g to remove fine precipitates, concentrating the supernatant under reduced pressure at 55-95 ℃ and-0.05-0.1 MPa, and concentrating the concentrate into a concentrated solution with the relative density of 1.05-1.25 to obtain a second filtrate;
(3) adding 2-4 times of volume of 90% V/V ethanol aqueous solution into the second filtrate obtained in the step (2) at the temperature of 5-65 ℃, fully stirring, naturally cooling to normal temperature, standing for 12-96 hours in an environment at the temperature of 1-25 ℃, collecting supernatant, filtering the supernatant through a filter material with the filter diameter of 0.2-1.0 micron, and collecting filtrate;
(4) combining the first filtrate obtained in the step (1) and the filtrate obtained in the step (3), fully and uniformly mixing, concentrating under reduced pressure at 55-95 ℃, and-0.05-0.1 MPa, and concentrating the filtrate to the volume of a concentrated solution: the feeding amount of the raw materials is 1 (1-4), and a concentrated solution is obtained, wherein:
the volume of the concentrated solution is measured by milliliter, and the feeding amount of the raw materials is measured by gram;
(5) weighing the picked tea leaves according to the formula ratio, flatly paving the tea leaves in a baking pan with the paving thickness of 0.5-8 cm, and placing the baking pan paved with the tea leaves in a baking oven for ventilation baking at 65-120 ℃ for 0.5-4 hours;
(6) uniformly spraying the concentrated solution obtained in the step (4) on the tea leaves in the baking pan for 1-10 times, and fully stirring to enable the liquid medicine to be completely adsorbed by the tea leaves, wherein:
between two adjacent spraying, continuously baking the tea leaves for 2-6 hours at 65-120 ℃ in a ventilating way, and uniformly turning over the materials every 0.5-2 hours;
(7) and (3) after the concentrated solution obtained in the step (4) is completely and uniformly mixed with the tea leaves in the tray, continuously performing ventilation baking at 65-120 ℃, uniformly turning over the materials every 0.5-2 hours until the tea leaves are dry and slightly pungent, gripping the tea leaves, enabling the tea leaves to be elastic and conglobate, and slightly touching the tea leaves with force to disperse tea leaves particles, thus preparing the safflower Suxin tea for reducing hypertension, hyperglycemia and hyperlipidemia and protecting the cardiovascular system.
5. The preparation method of the safflower perilla heart tea for reducing high blood pressure, high blood sugar and protecting the cardiovascular system according to claim 4, further comprising the step (8): and (3) adding the safflower perilla heart tea prepared in the step (7) for reducing the three highs and protecting the cardiovascular system into an automatic packaging machine for packaging, and carrying out aluminum-plastic packaging to obtain 1-5000 g of independent packages, thus obtaining the safflower perilla heart tea for reducing the three highs and protecting the cardiovascular system.
6. The method for preparing safflower perilla heart tea for reducing high blood pressure, high blood sugar and protecting cardiovascular as claimed in claim 4, wherein ethanol is recovered simultaneously during the process of vacuum concentration in step (4).
7. The method for preparing the safflower perilla heart tea for reducing high blood pressure, high blood sugar and protecting the cardiovascular system according to claim 4, wherein the tea leaves in the step (5) are any one or more of green tea, white tea, yellow tea, oolong tea, black tea and black tea.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010979113.6A CN111919934A (en) | 2020-09-17 | 2020-09-17 | Safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010979113.6A CN111919934A (en) | 2020-09-17 | 2020-09-17 | Safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111919934A true CN111919934A (en) | 2020-11-13 |
Family
ID=73334552
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010979113.6A Pending CN111919934A (en) | 2020-09-17 | 2020-09-17 | Safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111919934A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112386545A (en) * | 2020-12-18 | 2021-02-23 | 傅松涛 | Baijin tea extract gargle and preparation method thereof |
CN112471299A (en) * | 2020-12-18 | 2021-03-12 | 傅松涛 | Judai peach blossom tea with effects of relaxing bowel, reducing blood fat and losing weight and preparation method thereof |
CN112841352A (en) * | 2021-02-01 | 2021-05-28 | 青海大学 | Lipid-lowering cornus macrophylla seed oil tea as well as preparation method and application thereof |
CN115990211A (en) * | 2023-02-15 | 2023-04-21 | 北京鹤之堂中医研究院有限公司 | Traditional Chinese medicine probiotics composition for reducing blood pressure and preparation method thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007006203A1 (en) * | 2005-07-07 | 2007-01-18 | Shirong Duan | A capsule formulation for treating hypertension and coronary heart disease and process for preparation thereof |
CN101401601A (en) * | 2006-10-18 | 2009-04-08 | 吴建生 | Five-leaf tea for reducing blood pressure, blood fat and blood sugar |
WO2018053731A1 (en) * | 2016-09-21 | 2018-03-29 | 刘嘉辉 | Healthcare tea and preparation method therefor |
CN108815474A (en) * | 2018-09-07 | 2018-11-16 | 山东恒糅酒业有限公司 | A kind of health-care Chinese medicinal composition and preparation method thereof with lower hyperlipidemia, hypertension, hyperglycemia |
CN110150415A (en) * | 2019-06-20 | 2019-08-23 | 珠海林尚熙养生茶业有限公司 | A kind of three high tea-drinkings and preparation method thereof of tranquilizing the mind defaecation prevention |
-
2020
- 2020-09-17 CN CN202010979113.6A patent/CN111919934A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007006203A1 (en) * | 2005-07-07 | 2007-01-18 | Shirong Duan | A capsule formulation for treating hypertension and coronary heart disease and process for preparation thereof |
CN101401601A (en) * | 2006-10-18 | 2009-04-08 | 吴建生 | Five-leaf tea for reducing blood pressure, blood fat and blood sugar |
WO2018053731A1 (en) * | 2016-09-21 | 2018-03-29 | 刘嘉辉 | Healthcare tea and preparation method therefor |
CN108815474A (en) * | 2018-09-07 | 2018-11-16 | 山东恒糅酒业有限公司 | A kind of health-care Chinese medicinal composition and preparation method thereof with lower hyperlipidemia, hypertension, hyperglycemia |
CN110150415A (en) * | 2019-06-20 | 2019-08-23 | 珠海林尚熙养生茶业有限公司 | A kind of three high tea-drinkings and preparation method thereof of tranquilizing the mind defaecation prevention |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112386545A (en) * | 2020-12-18 | 2021-02-23 | 傅松涛 | Baijin tea extract gargle and preparation method thereof |
CN112471299A (en) * | 2020-12-18 | 2021-03-12 | 傅松涛 | Judai peach blossom tea with effects of relaxing bowel, reducing blood fat and losing weight and preparation method thereof |
CN112841352A (en) * | 2021-02-01 | 2021-05-28 | 青海大学 | Lipid-lowering cornus macrophylla seed oil tea as well as preparation method and application thereof |
CN115990211A (en) * | 2023-02-15 | 2023-04-21 | 北京鹤之堂中医研究院有限公司 | Traditional Chinese medicine probiotics composition for reducing blood pressure and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111919934A (en) | Safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular and preparation method thereof | |
CN103041118B (en) | Composition with effects of reducing blood sugar and reducing blood lipid | |
CN105079465A (en) | Composition capable of lowering blood glucose | |
CN108404019A (en) | Compound chicory root adjusts the solid articles and preparation method thereof of purine metabolic disturbance | |
CN101518595A (en) | Medical composition with functions of lowering lipid, reducing fat and oxidation resistance and preparation method thereof | |
CN108524673A (en) | A kind of Chinese medicine composition and its application | |
CN105250913B (en) | A kind of pharmaceutical composition for treating laying hen fatty liver syndrome | |
CN101084984A (en) | Porridge with intestines-moistening and eyesight-improving function | |
CN112970992A (en) | Solid beverage suitable for diabetes patients and preparation method thereof | |
CN107494817A (en) | A kind of hypoglycemic tea | |
KR20180079920A (en) | Composition for preventing, improving or treating hepatic fibrosis or liver cirrhosis comprising Cuscuta Semen extract | |
CN117599140A (en) | Traditional Chinese medicine composition for reducing blood sugar, blood pressure and blood fat and preparation and application thereof | |
CN110538311A (en) | Pure traditional Chinese medicine composition for controlling hypertension and preparation method thereof | |
CN110251591A (en) | A kind of pharmaceutical composition and its preparation method and application that aided blood pressure-lowering is hypoglycemic | |
CN108077485A (en) | A kind of blue or green money willow herbal tea and preparation method thereof | |
CN107712890A (en) | A kind of antitoxic heart-soothing and sedative cream taste and preparation method thereof | |
JP4516958B2 (en) | Anti-diabetic composition | |
CN109549206A (en) | A kind of thrombolysis and the functional food and preparation method thereof for preventing cardiovascular disease | |
CN103652059B (en) | The formula of bagged medicine tea and preparation method | |
KR100496622B1 (en) | Alcohol fermented food or pharmaceutical composition for prevention of obesity and process for preparation thereof | |
CN102988747B (en) | Aristida triseta electuary for reducing hypertension, hyperglycemia and hyperlipidemia and preparation method thereof | |
CN111905087A (en) | Health-care product composition for dispelling effects of alcohol and protecting liver | |
CN105311375A (en) | Composition for reducing blood lipid | |
CN101278940A (en) | Medicament composition for curing diabetic cardiovascular pathological changes and method of preparing the same | |
CN111955570A (en) | Ginseng white ganoderma lucidum tea capable of enhancing immunity and preventing tumors and production process thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201113 |
|
RJ01 | Rejection of invention patent application after publication |